Evidence map›Paper›PMID 32683881›Full record

ArticleAIDS research and human retroviruses2020

Short Communication: HIV-DRLink: A Tool for Reporting Linked HIV-1 Drug Resistance Mutations in Large Single-Genome Data Sets Using the Stanford HIV Database.

Wei Shao, Valerie F Boltz, Junko Hattori, Michael J Bale, Frank Maldarelli, John M Coffin, Mary F Kearney

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wei ShaoAdvanced Biomedical Computing Science, Frederick National Laboratory for Cancer Research (FNLCR) sponsored by the National Cancer Institute, Frederick, Maryland, USA.
Valerie F BoltzHIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, Maryland, USA.
Junko HattoriHIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, Maryland, USA.
Michael J BaleHIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, Maryland, USA.
Frank MaldarelliHIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, Maryland, USA.
John M CoffinDepartment of Molecular Biology and Microbiology, Tufts University, Boston, Massachusetts, USA.
Mary F KearneyHIV Dynamics and Replication Program, CCR, National Cancer Institute, Frederick, Maryland, USA.
National Cancer Institute · USTufts University · US

Funding

Ultrasensitive Single-Genome Sequencing to Study HIV Transmission and EvolutionZIABC011699 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KEARNEY, MARY · 2016 to 2024
$7.1M
Retrovirus Evolution and CancerR35CA200421 · NCI · TUFTS UNIVERSITY BOSTON · PI COFFIN, JOHN M · 2016 to 2022
$6.5M
NCI NIH HHS HHSN261200800001ENCI NIH HHS R35 CA200421
6 · The paper itself

Abstract

The prevalence of HIV-1 drug resistance is increasing worldwide and monitoring its emergence is important for the successful management of populations receiving combination antiretroviral therapy. It is likely that pre-existing drug resistance mutations linked on the same viral genomes are predictive of treatment failure. Because of the large number of sequences generated by ultrasensitive single-genome sequencing (uSGS) and other similar next-generation sequencing methods, it is difficult to assess each sequence individually for linked drug resistance mutations. Several software/programs exist to report the frequencies of individual mutations in large data sets, but they provide no information on linkage of resistance mutations. In this study, we report the HIV-DRLink program, a research tool that provides resistance mutation frequencies as well as their genetic linkage by parsing and summarizing the Sierra output from the Stanford HIV Database. The HIV-DRLink program should only be used on data sets generated by methods that eliminate artifacts due to polymerase chain reaction recombination, for example, standard single-genome sequencing or uSGS. HIV-DRLink is exclusively a research tool and is not intended to inform clinical decisions.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsAnti-Retroviral AgentsDrug Resistance, ViralHumansMutationAnti-HIV AgentsAnti-Retroviral AgentsHIVHIV-DRLinklinked drug resistance mutationsnext-generation sequencingStanford HIVdbuSGS

Identifiers

PMID32683881
PMCPMC7699007
OpenAlexW3044215375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.